AP3007A - Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant - Google Patents

Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant

Info

Publication number
AP3007A
AP3007A AP2010005333A AP2010005333A AP3007A AP 3007 A AP3007 A AP 3007A AP 2010005333 A AP2010005333 A AP 2010005333A AP 2010005333 A AP2010005333 A AP 2010005333A AP 3007 A AP3007 A AP 3007A
Authority
AP
ARIPO
Prior art keywords
rpe
thi
vaccine
optionally
ribosomal protein
Prior art date
Application number
AP2010005333A
Other languages
English (en)
Other versions
AP2010005333A0 (en
Inventor
Manuel Soto Alvarez
Daniel Ruiz Abanades
Carlos Alonso Bedate
Original Assignee
Leti Sl Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti Sl Lab filed Critical Leti Sl Lab
Publication of AP2010005333A0 publication Critical patent/AP2010005333A0/en
Application granted granted Critical
Publication of AP3007A publication Critical patent/AP3007A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2010005333A 2008-01-18 2009-01-14 Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant AP3007A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2192808P 2008-01-18 2008-01-18
EP08100634 2008-01-18
PCT/EP2009/050334 WO2009090175A1 (fr) 2008-01-18 2009-01-14 Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1

Publications (2)

Publication Number Publication Date
AP2010005333A0 AP2010005333A0 (en) 2010-08-31
AP3007A true AP3007A (en) 2014-10-31

Family

ID=39471089

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2010005333A AP3007A (en) 2008-01-18 2009-01-14 Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant

Country Status (19)

Country Link
US (1) US20110020405A1 (fr)
EP (2) EP2570427A1 (fr)
JP (2) JP2011509968A (fr)
CN (1) CN101977930B (fr)
AP (1) AP3007A (fr)
AU (1) AU2009204849B2 (fr)
BR (1) BRPI0906787A2 (fr)
CA (1) CA2712475A1 (fr)
CO (1) CO6280495A2 (fr)
DK (1) DK2231700T3 (fr)
ES (1) ES2486365T3 (fr)
HR (1) HRP20140447T1 (fr)
MA (1) MA32080B1 (fr)
MX (1) MX2010007831A (fr)
PL (1) PL2231700T3 (fr)
PT (1) PT2231700E (fr)
RU (1) RU2521499C2 (fr)
WO (1) WO2009090175A1 (fr)
ZA (1) ZA201005143B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
CN103270048B (zh) 2010-11-10 2016-11-23 热体实验室有限公司 新型佐剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039298A1 (fr) * 1998-12-23 2000-07-06 C.B.F. Leti S.A. Gene chimerique forme par les sequences d'adn codant pour les determinants antigeniques de quatre proteines de l. infantum, proteines codees par ledit gene, et compositions pharmaceutiques servant a prevenir et/ou traiter la leishmaniase chez l'animal et l'homme
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169995B1 (es) * 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20030072714A1 (en) * 2001-10-12 2003-04-17 Magill Alan J. Microfluidized leishmania lysate and methods of making and using thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO2000039298A1 (fr) * 1998-12-23 2000-07-06 C.B.F. Leti S.A. Gene chimerique forme par les sequences d'adn codant pour les determinants antigeniques de quatre proteines de l. infantum, proteines codees par ledit gene, et compositions pharmaceutiques servant a prevenir et/ou traiter la leishmaniase chez l'animal et l'homme

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BADARO R ET AL: "Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal Leishmaniasis refractory to antimony: A case report." THE BRAZILIAN JOURNAL OF INFECTIOUS DISEASES : AN OFFICIAL PUBLICATION OF THE BRAZILIAN SOCIETY OF INFECTIOUS DISEASES AUG 2001, vol. 5, no. 4, August 2001 (2001-08), pages 223-232, XP002484147 *
IBORRA SALVADOR ET AL: "The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice." INFECTION AND IMMUNITY NOV 2003, vol. 71, no. 11, November 2003 (2003-11), pages 6562-6572, XP002484146 *
SANTAREM ET AL: "Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment" IMMUNOLOGY LETTERS, AMSTERDAM, NL, vol. 101, no. 1, 15 October 2005 (2005-10-15), pages 18-23, XP005073261 *
SJOLANDER A ET AL: "Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 20, 1 December 1998 (1998-12-01), pages 2077-2084, XP004138459 ISSN: 0264-410X *

Also Published As

Publication number Publication date
CN101977930A (zh) 2011-02-16
PT2231700E (pt) 2014-07-31
HRP20140447T1 (hr) 2014-07-04
US20110020405A1 (en) 2011-01-27
WO2009090175A1 (fr) 2009-07-23
AU2009204849A1 (en) 2009-07-23
BRPI0906787A2 (pt) 2015-08-18
CN101977930B (zh) 2014-12-17
CO6280495A2 (es) 2011-05-20
AU2009204849B2 (en) 2013-10-03
AP2010005333A0 (en) 2010-08-31
MA32080B1 (fr) 2011-02-01
EP2231700A1 (fr) 2010-09-29
PL2231700T3 (pl) 2014-09-30
RU2010134427A (ru) 2012-02-27
JP2011509968A (ja) 2011-03-31
RU2521499C2 (ru) 2014-06-27
CA2712475A1 (fr) 2009-07-23
HK1150291A1 (en) 2011-11-18
EP2570427A1 (fr) 2013-03-20
MX2010007831A (es) 2011-06-20
EP2231700B1 (fr) 2014-05-07
ES2486365T3 (es) 2014-08-18
ZA201005143B (en) 2011-12-28
DK2231700T3 (da) 2014-07-14
JP2015180638A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
EP1988918A4 (fr) Compositions d'adjuvant et de vaccin
GB0607088D0 (en) Vaccine
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
GB2453475B (en) Live vaccine strain
IL199622A0 (en) Foxp3 peptide vaccine
ZA200902937B (en) Prophylactic tuberculosis vaccine
ZA200902155B (en) IPV-DPT vaccine
AP3007A (en) Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant
EP2337847A4 (fr) Adjuvants pour des vaccins
GB0625587D0 (en) Live vaccine strain
GB0805675D0 (en) Adjuvanted vaccine
ZA200901592B (en) Vaccine
TWI346557B (en) Adjuvant and vaccine includes the same
GB2443591B (en) Adjuvanted vaccine
GB0625596D0 (en) Live vaccine strain
GB0625593D0 (en) Vaccine
TWI317637B (en) Vaccine and manufacture method thereof
HK1157682A (en) Vaccine adjuvant combinations
GB0608962D0 (en) Vaccine
GB0619821D0 (en) Vaccine
GB0620337D0 (en) Vaccine
GB0614254D0 (en) Vaccine
GB0607087D0 (en) Vaccine
GB0606256D0 (en) Anti-atheroma vaccine
GB0620336D0 (en) Vaccine